Acasti Pharma Inc. (ACST)’s Financial Results Comparing With Cue Biopharma Inc. (NASDAQ:CUE)

This is therefore a contrasting of the profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation in Acasti Pharma Inc. (NASDAQ:ACST) and Cue Biopharma Inc. (NASDAQ:CUE). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acasti Pharma Inc. N/A 0.00 N/A -1.22 0.00
Cue Biopharma Inc. N/A 186.84 37.80M -1.99 0.00

Table 1 demonstrates Acasti Pharma Inc. and Cue Biopharma Inc.’s gross revenue, earnings per share and valuation.


Table 2 demonstrates the net margins, return on equity and return on assets of Acasti Pharma Inc. and Cue Biopharma Inc.

Net Margins Return on Equity Return on Assets
Acasti Pharma Inc. 0.00% 0% 0%
Cue Biopharma Inc. 0.00% -67.9% -62.3%

Institutional & Insider Ownership

The shares of both Acasti Pharma Inc. and Cue Biopharma Inc. are owned by institutional investors at 3.77% and 20.8% respectively. About 8.49% of Acasti Pharma Inc.’s share are owned by insiders. Comparatively, 0.3% are Cue Biopharma Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acasti Pharma Inc. 0% 0.93% 56.52% 118.84% 9.09% 29.82%
Cue Biopharma Inc. 6.07% 33.27% 29.96% -20.35% -54.02% 44.89%

For the past year Acasti Pharma Inc. was less bullish than Cue Biopharma Inc.


On 4 of the 7 factors Acasti Pharma Inc. beats Cue Biopharma Inc.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company's biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.